Bicycle Therapeutics plc announced Mike Hannay, D.Sc., FRPharmS, promoted to Chief Product and Supply Chain Officer. Since joining Bicycle Therapeutics in April 2022, Professor Hannay has advanced the company?s chemistry, manufacturing and controls (CMC) capabilities and drug manufacturing priorities, including preparations and buildout for the potential commercial launch of BT8009. Over the course of his career, through his work at Sanofi, Schwarz Pharma, Teva Pharmaceuticals and AstraZeneca, Professor Hannay has launched more than 40 medicines.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.18 USD | -0.81% | -5.94% | +22.68% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.68% | 946M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.44% | 22.28B | |
-11.90% | 22.41B | |
-4.45% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- BCYC Stock
- News Bicycle Therapeutics plc
- Bicycle Therapeutics plc Announces Promotion of Mike Hannay as Chief Product and Supply Chain Officer